Kala Pharmaceuticals Inc (KALA) - Total Liabilities
Based on the latest financial reports, Kala Pharmaceuticals Inc (KALA) has total liabilities worth $2.49 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kala Pharmaceuticals Inc - Total Liabilities Trend (2013–2025)
This chart illustrates how Kala Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See KALA working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Kala Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Kala Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Forian Inc
NASDAQ:FORA
|
USA | $14.35 Million |
|
NS Co. Ltd
KQ:217820
|
Korea | ₩224.22 Billion |
|
Postmedia Network Canada Corp
TO:PNC-B
|
Canada | CA$553.60 Million |
|
ETHZilla Corporation
NASDAQ:ETHZ
|
USA | $66.88 Billion |
|
Great Elm Group Inc
NASDAQ:GEG
|
USA | $71.94 Million |
|
TEKNA HOLDING ASA NK 2
F:8VB
|
Germany | €18.33 Million |
|
Hannan Metals Ltd
V:HAN
|
Canada | CA$200.47K |
|
Oswal Greentech Limited
NSE:OSWALGREEN
|
India | Rs481.96 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Kala Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see KALA market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kala Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kala Pharmaceuticals Inc (2013–2025)
The table below shows the annual total liabilities of Kala Pharmaceuticals Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.49 Million | -94.22% |
| 2024-12-31 | $43.15 Million | -10.93% |
| 2023-12-31 | $48.45 Million | -28.60% |
| 2022-12-31 | $67.85 Million | -44.67% |
| 2021-12-31 | $122.62 Million | +0.83% |
| 2020-12-31 | $121.61 Million | -2.42% |
| 2019-12-31 | $124.63 Million | +7.46% |
| 2018-12-31 | $115.98 Million | +338.42% |
| 2017-12-31 | $26.45 Million | -80.27% |
| 2016-12-31 | $134.09 Million | +841.58% |
| 2015-12-31 | $14.24 Million | +68.33% |
| 2014-12-31 | $8.46 Million | +23.14% |
| 2013-12-31 | $6.87 Million | -- |
About Kala Pharmaceuticals Inc
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more